The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line / 中华男科学杂志
National Journal of Andrology
; (12): 617-620, 2009.
Article
Dans Zh
| WPRIM
| ID: wpr-241290
Responsable en Bibliothèque :
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effect of the mammalian target of rapamycin (mTOR) inhibitor CCI-779 on the chemosensitivity of androgen-independent prostate cancer cell line PC-3.</p><p><b>METHODS</b>Prostate cancer cells PC-3 were cultured and treated with CCI-779, Paclitaxel and combination of the two. Then the inhibitory effects of the three medications on the growth of the PC-3 cells were determined by MTT, and the their cell cycle and apoptosis were detected by flow cytometry.</p><p><b>RESULTS</b>Compared with the control group, the three medications all significantly inhibited the proliferation of the PC-3 cells, and the combined method even enhanced the effect. Flow cytometry showed that CCI-779 and Paclitaxel blocked the cell cycle mainly in the G1/G2 stage, while the combined medication mainly in the G0/G1 stage. Significantly increased apoptosis of the PC-3 cells was observed in the three medication groups as compared with the control group (P < 0.01).</p><p><b>CONCLUSION</b>CCI-779 can inhibit the proliferation of PC-3 cells and enhance the chemosensitivity of prostate cancer.</p>
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pharmacologie
/
Tumeurs de la prostate
/
Cycle cellulaire
/
Paclitaxel
/
Sirolimus
/
Lignée cellulaire tumorale
/
Inhibiteurs de protéines kinases
/
Traitement médicamenteux
/
Association de médicaments
/
Antinéoplasiques
Limites du sujet:
Humans
/
Male
langue:
Zh
Texte intégral:
National Journal of Andrology
Année:
2009
Type:
Article